Table 1.
Pyogenic (n = 132) | Amoebic (n = 9) | ||
---|---|---|---|
Sex | Male | 84 (63.6%) | 9 (100.0%) |
Age (years) | Median (IQR) | 68 (51–78) | 41 (37–51) |
Ethnicity | White (British or Other) | 47 (35.6%) | 1 (11.1%) |
Indian/Pakistani | 33 (25.0%) | 5 (55.6%) | |
Asian | 19 (14.4%) | 3 (33.3%) | |
Other | 17 (12.9%) | 0 (0.0%) | |
Caribbean | 13 (9.9%) | 0 (0.0%) | |
African | 3 (2.3%) | 1 (11.1%) | |
Number of organismsa | 0 | 51 (38.6%) | – |
1 | 62 (47.0%) | – | |
2 | 9 (6.8%) | – | |
3 | 8 (6.1%) | – | |
4 | 2 (1.5%) | ||
Organism | None | 51 (38.6%) | – |
Grouped for analysis | Enterobacteriaceae | 14 (10.6%) | – |
E. Coli | 21 (15.9%) | ||
Klebsiella spp. | 21 (15.9%) | ||
S. milleri group | 19 (14.4%) | – | |
Other Strep spp. | 7 (5.3%) | ||
Anaerobe | 16 (12.1%) | – | |
Grouped as ‘other’ for analysis | Enterococcus | 5 (3.8%) | |
Staphylococcus aureus | 1 (0.8%) | – | |
Pseudomonas aeriginosa | 2 (1.5%) | – | |
Other (Anaeroglobus, Haemophilus, Corynebacterium, Sutterella) | 5 (3.8%) | – | |
Number of abscesses identified | 1 | 75 (56.8%) | 7 (77.8%) |
2 | 19 (14.4%) | 1 (11.1%) | |
≥3 | 38 (28.8%) | 1 (11.1%) | |
Maximum diameter (cm) | Median (IQR) | 6.1 (4.8–9.0), n = 118 | 7.3 (5.8–8.8), n = 8 |
Loculated | 52 (39.4%) | 1 (11.1%) | |
Antimicrobial resistanceb | 45 (34.1%) | – | |
Abscess aspirated/drained | 79 (59.9%) | 6 (66.7%) | |
Diabetic | 36 (27.3%) | 3 (33.3%) | |
Recent travel (< 1 year) | 23 (21.1%) | 6 (66.7%) | |
Immunosuppression (chemotherapy, steroids, immunotherapy or combination in previous year) | 18 (13.6%) | 0 (0.0%) | |
Died within 30 days | 7 (5.3%) | 0 (0.0%) | |
Died within 6 months | 20 (15.2%) | 0 (0.0%) |
ain total, 111 microorganisms were isolated from 81 pyogenic liver abscess patients
bResistance was detected to one or more antimicrobial agents in 45/132 patients and in 54/111 (48.7%) of microorganisms